Alterity TherapeuticsFRA:PBN -3.55%26 FCF Yield % is -14.54 as of Jun. 29, 2026. GuruFocus rates FRA:PBN with a GF Score™ of 26/100. Among 1,415 Biotechnology companies, Alterity Therapeutics ranks worse than 59.65% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Alterity Therapeutics FCF Yield % Related Terms
Alterity Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Alterity Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBN vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Alterity Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alterity Therapeutics (FRA:PBN) has a FCF Yield % of -14.54 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #844 out of 1415 companies in the Biotechnology industry, placing it in the top 59.6%.
Is Alterity Therapeutics' FCF Yield % too high?
Alterity Therapeutics' current FCF Yield % is -14.54. Based on the distribution chart, Alterity Therapeutics ranks #844 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #844 out of 1415 companies for FCF Yield %. This places Alterity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current FCF Yield % is -14.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (FRA:PBN) has a current FCF Yield % of -14.54. The current FCF Yield % is -14.54. Alterity Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Alterity Therapeutics (FRA:PBN), the current FCF Yield % is -14.54 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
26GF Score
Get the complete analysis for FRA:PBN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBN has been successfully added to your 
